Program
telisotuzumab adizutecan
Also written as “Telisotuzumab Adizutecan”, “RC148 plus Telisotuzumab adizutecan” and “ABBV-400”.
In AbbVie’s pipeline, c-Met
. Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Neoplasms · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Hepatocellular, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 1717 open or running | phase 3since May 27, 2025 | Aug 30, 2021 | Dec 2026phase 2 · NCT06107413 |
| RemeGen | 11 open or running | phase 2since Oct 12, 2026 | Oct 12, 2026 | Jul 2028phase 2 · NCT07895355 |
- Named in AbbVie’s own pipeline as
Temab-A (ABBV-400)
, phase 3, as of Jul 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Aug 30, 2021.
- Oct 3, 2024Phase 2 study in Adenocarcinoma Of EsophagusAbbVie · NCT06628310 · 185 enrolled · United States, Belgium, Canada and more
- Jan 9, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungAbbVie · NCT06772623 · 252 planned · United States, Argentina, Australia and more
- Feb 6, 2025Phase 2 study in Colorectal NeoplasmsAbbVie · NCT06820463 · 390 planned · United States, Australia, Austria and more
- May 27, 2025Phase 3 study in NeoplasmsAbbVie · NCT07005102 · 854 planned · United States, Australia, Belgium and more
- Jun 10, 2025Phase 2 study in Colorectal NeoplasmsAbbVie · NCT07023289 · 140 planned · United States, Belgium, Denmark and more
- Aug 28, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungAbbVie · NCT07155187 · 490 planned · United States, Australia, Austria and more
- Sep 22, 2025Phase 2 study in Solid Tumors Harboring MET AmplificationAbbVie · NCT07196644 · 100 planned · United States, Israel, Japan and more
- Mar 13, 2026Phase 3 study in Metastatic Pancreatic Ductal AdenocarcinomaAbbVie · NCT07490301 · 900 planned · United States, Australia, Israel and more
- Apr 7, 2026Phase 3 study in Colorectal NeoplasmsAbbVie · NCT07525206 · 990 planned · United States, Belgium, China and more
- Jul 30, 2026Phase 2 study in Squamous Cell Carcinoma of Head and NeckAbbVie · NCT07744126 · 150 planned · United States, Japan, Taiwan
- Aug 13, 2026Phase 2 study in NeoplasmsAbbVie · NCT07769502 · 168 planned · United States, Israel, Japan and more
- Sep 10, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungAbbVie · NCT07821684 · 660 planned
- Oct 5, 2026Primary completion moved from 2031-12 to 2036-11Date moved laterphase 3 · +59 months · NCT07005102
- Oct 12, 2026RemeGen’s first study: phase 2 study in Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line TherapyNew to RemeGenRemeGen · NCT07895355 · 412 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in NeoplasmsAbbVie · NCT06107413
- Aug 2027Primary completion: phase 2 study in Colorectal NeoplasmsAbbVie · NCT06614192
- Sep 2027Primary completion: phase 1 study in Carcinoma, HepatocellularAbbVie · NCT06084481
- Nov 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungAbbVie · NCT06772623
TargetBeta
“c-Met”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) ”NCIt, by rule
Other programs on MET
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Crizotinibrule | Pfizer | phase 4 | 31 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| amivantamabrule | Johnson & Johnson | phase 3 | 16 |
| vebreltinibrule | beijing-pearl-biotechnology-limited-liability-company | phase 3 | 9 |
| glumetinibrule | Haihe Biopharma | phase 3 | 8 |
| vilzemetkib | Sino Biopharmaceutical | phase 3 | 8 |
| dalmelitinib | Hansoh Pharmaceutical Group | phase 3 | 7 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| SHR-1826 | Jiangsu HengRui Medicine | phase 2 | 7 |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 5 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07895355Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy · China | 2 | Not yet recruiting | RemeGen | Jul 2028 | 412 |
| NCT07821684Carcinoma, Non-Small-Cell Lung | 3 | Not yet recruiting | AbbVie | Mar 2030 | 660 |
| NCT07769502Neoplasms · United States, Israel, Japan and more | 2 | Recruiting | AbbVie | Sep 2028 | 168 |
| NCT07744126Squamous Cell Carcinoma of Head and Neck · United States, Japan, Taiwan | 2 | Recruiting | AbbVie | Oct 2029 | 150 |
| NCT07525206Colorectal Neoplasms · United States, Belgium, China and more | 3 | Recruiting | AbbVie | May 2029 | 990 |
| NCT07490301Metastatic Pancreatic Ductal Adenocarcinoma · United States, Australia, Israel and more | 3 | Recruiting | AbbVie | Jun 2031 | 900 |
| NCT07196644Solid Tumors Harboring MET Amplification · United States, Israel, Japan and more | 2 | Recruiting | AbbVie | Dec 2030 | 100 |
| NCT07155187Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Recruiting | AbbVie | Sep 2030 | 490 |
| NCT07023289Colorectal Neoplasms · United States, Belgium, Denmark and more | 2 | Recruiting | AbbVie | Nov 2029 | 140 |
| NCT07005102Neoplasms · United States, Australia, Belgium and more | 3 | Recruiting | AbbVie | Nov 2036 | 854 |
| NCT06820463Colorectal Neoplasms · United States, Australia, Austria and more | 2 | Recruiting | AbbVie | Mar 2028 | 390 |
| NCT06772623Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 2 | Recruiting | AbbVie | Nov 2027 | 252 |
| NCT06628310Adenocarcinoma Of Esophagus · United States, Belgium, Canada and more | 2 | Active, not recruiting | AbbVie | Oct 2030 | 185 |
| NCT06614192Colorectal Neoplasms · United States, Australia, Israel and more | 2 | Active, not recruiting | AbbVie | Aug 2027 | 74 |
| NCT06464692Colorectal Neoplasms · China | 1 | Active, not recruiting | AbbVie | Dec 2027 | 31 |
| NCT06107413Neoplasms · United States, Belgium, Germany and more | 2 | Active, not recruiting | AbbVie | Dec 2026 | 280 |
| NCT06084481Carcinoma, Hepatocellular · United States, Australia, Israel and more | 1 | Recruiting | AbbVie | Sep 2027 | 325 |
| NCT05029882Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 1 | Active, not recruiting | AbbVie | Nov 2027 | 520 |
How it is read
Names in the registry
- “Telisotuzumab Adizutecan”, 12 entries
- “RC148 plus Telisotuzumab adizutecan”, 4 entries
- “ABBV-400”, 3 entries
- “Telisotuzumab adizutecan”, 2 entries
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 6 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Neoplasms, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Carcinoma, Hepatocellular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.